Molecular characterisation of breast cancer: the mutational landscape

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer

Metabolism in malignant tumors: a new approach for treating breast cancer

Criteria required before implementation of whole genome arrays in clinical practice

Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer

Implementing symptom guidelines

Personalised medicine and nursing

Addressing the issue of personalised care

Oncology nurses should take the lead

Communication in genetics and genomics

Mouse models of metastatic breast cancer

Advanced breast cancer consensus and the latest on triple negative breast cancer